Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Rivers Inc - Class A V.AIMVP


Primary Symbol: CNPOF

Canopy Rivers Inc is a venture capital investment and operating platform structured to pursue investment opportunities in the global cannabis sector. The company has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the cannabis sector. The investments take the form of production-linked royalties, secured debt, newly formed joint ventures, and a variety of equity and equity-linked instruments.


OTCPK:CNPOF - Post by User

Post by proneon Mar 20, 2020 8:38am
97 Views
Post# 30829658

Riv is connected to Terr & it grows Hemp & is USA based.....

Riv is connected to Terr & it grows Hemp & is USA based.....

CBD is in the Spotlight as Consumer Appetite for Health Products Grows

23 hours ago by PR Newswire
Companies Mentioned: CGCAPHA
 

Over the past several years, the sale of cannabidiol-based (CBD) products has rapidly increased due to varied, yet successful, legalization efforts. 

Specifically, in regions such as the U.S. and Canada, consumers have shown a strong demand to purchase such products in retailers, where CBD is sold in various forms such as topicals, beverages, tinctures, and patches.

---> Notably, major retail corporations such as Amazon, Walgreens, and CVS have all decided to sell CBD products in-store as well as on their online platforms.

The passage of the U.S. Farm Bill in late 2018, which legalized the commercialization of hemp-derived products, was a major contribution to the acceleration of the market. 

Shortly after the passage of the bill, retailers throughout the country began to stock up on CBD products as consumers became increasingly inquisitive. 

At the market's inception, most consumers generally had little to no knowledge about CBD, except for the fact that it was derived from the cannabis plant. With hemp-derived CBD growing in popularity, in particular within the health, wellness, and anti-pharma segments, 

---> the market is on track to grow to USD 23.7 Billion by 2023, according to the Brightfield Group.

Generally, most consumers use CBD products for medicinal purposes. Similarly, retailers are advertising CBD products as therapeutic treatments, however, there is still a large recreational market for the industry. 

Primarily, most consumers intake CBD to treat a wide range of medical conditions such as chronic pain, mood disorders, neurological disorders, and diabetes. In the healthcare industry, most independent pharmacies have already begun selling CBD products. 

While there are many ways to consume CBD, the oils marketplace is expected to be the fastest growing segment within the overall CBD sector. 

For instance, the CBD oil market size will grow by USD 3.52 Billion during the period of 2020 to 2024, according to Technavio. 

"The 29 U.S. states reporting licensed hemp cultivation acreage total almost half a million acres in combined cultivation land area, which is a massive increase compared to 2018 figures of a total land area barely over 100,000 acres. 

While there continues to be uncertainty and a healthy amount of confusion around hemp cultivation for CBD production, it is clear that demand is nonetheless continuing to rise across the U.S.," noted Giadha Aguirre de Carcer, New Frontier Data CEO and Founder. 

"As states issue more licenses, consumer demand increases, and mass-market retailers such as CVS and Walgreens continue to expand their own product offerings, we expect the FDA may be forced to provide further regulatory clarifications sooner rather than later."

<< Previous
Bullboard Posts
Next >>